Related Experiment Video
Updated: Dec 31, 2025
Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
Published on: March 1, 2011
Evaluation of IL-17 and IL-35 Serum Levels in Patients with Preeclampsia
Atefeh Batebi1,2, Bahia Namavar-Jahromi1,2, Mohammad Ali-Hassanzadeh3,4
1Department of Gynecology and Obstetrics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Insights
Elevated serum levels of Interleukin-35 (IL-35) are associated with pre-eclampsia severity in Iranian women. Interleukin-17 (IL-17) levels did not differ significantly between groups.
Area of Science:
- Immunology
- Obstetrics
- Reproductive Medicine
Background:
- Pre-eclampsia (PE) is a common pregnancy complication linked to maternal and prenatal morbidity.
- Cytokine network imbalances, including inflammatory and anti-inflammatory cytokines, are implicated in PE.
- Limited data exists on the specific roles of Interleukin-35 (IL-35) and Interleukin-17 (IL-17) in PE pathogenesis.
Purpose of the Study:
- To investigate and compare serum levels of IL-35 and IL-17 in Iranian women with pre-eclampsia versus healthy pregnant women.
- To explore the potential correlation between IL-35 and IL-17 levels and the severity of pre-eclampsia.
Main Methods:
- Serum samples were collected from 100 pre-eclamptic and 100 healthy pregnant women, matched for key demographic factors.
- Enzyme-Linked Immunosorbent Assay (ELISA) was employed to quantify serum IL-35 and IL-17 concentrations.
- Statistical analysis included t-tests and one-way ANOVA with Tukey Post-Hoc tests (p<0.05 significance).
Main Results:
- Serum IL-35 levels were significantly elevated in pre-eclamptic women compared to healthy controls (p<0.001).
- No significant difference in serum IL-17 levels was observed between pre-eclamptic and healthy pregnant women (p=0.73).
- Higher IL-35 levels correlated with increased pre-eclampsia severity (severe vs. mild PE; p<0.001) and higher proteinuria (p<0.001).
Conclusions:
- Elevated serum IL-35 may serve as a valuable biomarker for assessing pre-eclampsia severity.
- The findings suggest a specific role for IL-35 in the pathophysiology or progression of pre-eclampsia.
- IL-17 does not appear to be a significant indicator in this cohort of Iranian pre-eclamptic women.
Background:
Pre-eclampsia (PE) is the most common pregnancy complication affecting 2-8% of all pregnancies. PE could lead to maternal and prenatal morbidity. Imbalanced cytokine network and altered levels of several inflammatory and anti-inflammatory cytokines have been reported in PE. Because of scare information regarding the roles of IL-17 and IL-35 in PE, the current study aimed to investigate the serum level of these cytokines in a group of Iranian women suffering from PE.
Methods:
Serum samples were collected from 100 pre-eclamptic and 100 healthy pregnant women. Patients and controls were matched for age, ethnicity and body mass index. The level of IL-35 and IL-17 were evaluated by ELISA technique. T test and one-way ANOVA with Tukey Post-Hoc test were used for analysis and p<0.05 were assumed significant.
Results:
The serum level of IL-35 was increased in pre-eclamptic subjects as compared with healthy pregnant women (p<0.001). There was no significant difference in the serum level of IL-17 between pre-eclamptic and healthy pregnant women (p=0.73). Moreover, the results of the present study also showed that the pregnant women with severe pre-eclampsia had higher level of IL-35 in their sera when compared to those with mild form of the disease (p<0.001). In addition, the serum level of IL-35 was significantly elevated in women with higher proteinuria (p<0.001).
Conclusion:
Based on the our results, it seems that elevated levels of IL-35 in sera of pre-eclamptic women might work as a marker to evaluate the severity of the preeclampsia.
More Related Videos
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017